MedTrace Logo

Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms

NCT01016444 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 311

Last updated 2021-09-01

No results posted yet for this study

Summary

The hypothesis to be tested is that acutely ill asthmatics who do not resolve their attacks following standard doses of albuterol and require admission to hospital have single nucleotide polymorphisms of their B2 adrenergic receptors that lower B2 agonist responsivity.

Conditions

  • Acute Asthma

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • MetroHealth Medical Center

    lead OTHER

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-07-29
Completion
2011-07-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01016444 on ClinicalTrials.gov